2Perkins FR,Skirving AP.Callus formation and the rate of healing of femoral fracture in patients with head injuries [J].J Bone Joint sueg (Br), 1987,69:521-524.
4Bone HG, Hosking D, Devogelaer JP, et al. Ten years'experience with alendronate forosteoporosis in postmenopausalwomen [J]. N Engl J Med, 2004,350:1189-1199.
6Lin JH.Bisphosphonates:A review of their pharmacokineie properties [J]. Bone, 1996,18(2):75-75.
7Fleisch HA.Bisphosphonates:preclinical aspects and use in osteoporosis[J ].Ann Med, 1997,29( 1 ):55-62.
8Romanello M,Bivi N,Pines A,et al. Bisphosphonates activate nucleotide receptors signaling and induce the expression of Hsp-90 in osteoblast-2 like cell lines[J]. Bone,2006,39(4):739-753.
8Deal C.The use of intermittent human parathyroid hormone as a treatment for osteoporosis.Curr Rheumatol Rep,2004,6:49-58.
9Brixen KT,Christensen PM,Ejersted C,et al.Teriparatide (biosynthetic human parathyroid hormone 1-34):a new paradigm in the treatment of osteoporosis.Basic Clin Pharmacol Toxicol,2004,94:260-270.
10Sharpe M,Noble S,Spencer CM.Alendronate:an update of its use in osteoporosis.Drugs,2001,61:999-1039.
